Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Iopamidol
Drug ID BADD_D01181
Description Iopamidol is a contrast agent developed by Bracco with nonionic, low-osmolar properties.
Indications and Usage Not Available
Marketing Status approved
ATC Code V08AB04
DrugBank ID DB08947
KEGG ID D01797
MeSH ID D007479
PubChem ID 65492
TTD Drug ID D0O2HQ
NDC Product Code 68225-077; 0270-1412; 68225-078; 68225-100; 0270-1315; 0270-1317; 0270-1411; 70436-126; 62331-006; 0270-1316; 68225-076; 0270-1314; 70436-124; 57876-222
UNII JR13W81H44
Synonyms Iopamidol | Jopamidol | Gastromiro | Iopamidol, (+-)-Isomer | Iopamidol, (R)-Isomer | Iopamidol, Sodium Salt, (S)-Isomer | Iopamiro | Isovue 370 | Niopam | Solutrast | Solutrast 370 | Solutrast Gastro | SQ 13,396 | B-15,000 | B 15,000 | B15,000 | B-15000 | B 15000 | B15000 | Isovue
Chemical Information
Molecular Formula C17H22I3N3O8
CAS Registry Number 60166-93-0
SMILES CC(C(=O)NC1=C(C(=C(C(=C1I)C(=O)NC(CO)CO)I)C(=O)NC(CO)CO)I)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Cerebral haematoma24.07.04.006; 17.08.01.014--Not Available
Skin burning sensation23.03.03.021; 17.02.06.009--Not Available
Haemorrhage24.07.01.002--Not Available
Hypoaesthesia oral07.05.05.003; 17.02.06.0210.079670%Not Available
Paraesthesia oral17.02.06.008; 07.05.05.0350.059041%Not Available
Toxic skin eruption12.03.01.073; 23.03.05.003; 10.01.01.0080.007113%Not Available
Pulseless electrical activity02.03.04.0200.007113%Not Available
Nuchal rigidity17.05.02.006; 15.05.04.005--Not Available
Peripheral nerve palsy17.01.04.017--Not Available
Vasodilation procedure25.03.01.001--Not Available
Hot flush24.03.01.005; 21.02.02.001; 08.01.03.027--
Adverse event08.06.01.010--Not Available
Electrocardiogram change13.14.05.014--Not Available
Infarction24.04.02.017--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Renal injury20.01.03.015; 12.01.05.001--Not Available
Ill-defined disorder08.01.03.049--Not Available
Sensation of foreign body08.01.09.0020.034856%Not Available
Cardiac fibrillation02.03.02.021--Not Available
Grimacing17.02.05.029--Not Available
Infusion site extravasation08.02.05.007; 12.07.05.0080.044103%
Immediate post-injection reaction10.01.03.032; 08.06.01.019--Not Available
Adverse reaction08.06.01.0180.048371%Not Available
Oropharyngeal discomfort22.12.03.015; 07.05.05.0080.036278%Not Available
Oropharyngeal pain07.05.05.004; 22.12.03.016--
Acute kidney injury20.01.03.0160.120928%
Mouth swelling23.04.01.020; 10.01.05.020; 07.05.04.0070.007113%Not Available
Respiratory symptom22.12.02.013--Not Available
Nasal pruritus22.04.03.018--Not Available
Multiple organ dysfunction syndrome08.01.03.0570.007113%
The 9th Page    First    Pre   9 10    Next   Last    Total 10 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene